Affiliation:
1. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
Subject
Psychiatry and Mental health,Cellular and Molecular Neuroscience,Geriatrics and Gerontology,Neurology (clinical),Developmental Neuroscience,Health Policy,Epidemiology
Reference7 articles.
1. Detection of Alzheimer's disease amyloid beta 1‐42, p‐tau, and t‐tau assays
2. FDA permits marketing of new test to improve diagnosis of Alzheimer's disease. Accessed Jan 3 2024:www.fda.gov/new‐events/press‐announcements/fda‐permits‐marketing‐new‐test‐improve‐diagnosis‐alzheimers‐disease
3. Roche Alzheimer's disease cerebrospinal fluid (CSF) assays receive FDA clearance supporting more accurate and timely diagnosis. Accessed Jan 3 2024:https://diagnostics.roche.com/us/en/news‐listing/2022/roche‐alzheimers‐disease‐cerobrospinal‐fluid‐assays‐receive‐fda‐clearance.html
4. The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review
5. The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau